Meloxicam

Meloxicam
Clinical data
Trade names	Mobic, others
AHFS/Drugs.com	Monograph
MedlinePlus	a601242
License data	US DailyMed: Meloxicam;
Pregnancy; category	AU: C;
Routes of; administration	By mouth, intravenous
Drug class	Nonsteroidal anti-inflammatory drug (NSAID)
ATC code	M01AC06 (WHO) M01AC56 (WHO), N01BB59 (WHO);
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; UK: POM (Prescription only); US: ℞-only; EU: Rx-only;
Pharmacokinetic data
Bioavailability	89%
Protein binding	99.4%
Metabolism	Liver (CYP2C9 and 3A4-mediated)
Elimination half-life	20 hours
Excretion	Urine and feces equally
Identifiers
	IUPAC name 4-Hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide;
CAS Number	71125-38-7 ;
PubChem CID	5281106;
IUPHAR/BPS	7220;
DrugBank	DB00814 ;
ChemSpider	10442740 ;
UNII	VG2QF83CGL;
KEGG	D00969 ;
ChEBI	CHEBI:6741 ;
ChEMBL	ChEMBL599 ;
PDB ligand	MXM (PDBe, RCSB PDB);
CompTox Dashboard (EPA)	DTXSID1020803 ;
ECHA InfoCard	100.113.257
Chemical and physical data
Formula	C14H13N3O4S2
Molar mass	351.40 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Cc1cnc(s1)NC(=O)C\3=C(/O)c2ccccc2S(=O)(=O)N/3C;
	InChI InChI=1S/C14H13N3O4S2/c1-8-7-15-14(22-8)16-13(19)11-12(18)9-5-3-4-6-10(9)23(20,21)17(11)2/h3-7,18H,1-2H3,(H,15,16,19) ; Key:ZRVUJXDFFKFLMG-UHFFFAOYSA-N ;
	(what is this?) (verify)

Meloxicam, sold under the brand name Mobic among others, is a nonsteroidal anti-inflammatory drug (NSAID) used to treat pain and inflammation in rheumatic diseases and osteoarthritis. It is taken by mouth or given by injection into a vein. It is recommended that it be used for as short a period as possible and at a low dose.

Common side effects include abdominal pain, dizziness, swelling, headache, and a rash. Serious side effects may include heart disease, stroke, kidney problems, and stomach ulcers. Use is not recommended in the third trimester of pregnancy. It blocks cyclooxygenase-2 (COX-2) more than it blocks cyclooxygenase-1 (COX-1). It is in the oxicam family of chemicals and is closely related to piroxicam.

Meloxicam was patented in 1977 and approved for medical use in the United States in 2000. It was developed by Boehringer Ingelheim and is available as a generic medication. In 2022, it was the 29th most commonly prescribed medication in the United States, with more than 18 million prescriptions. An intravenous version of meloxicam (Anjeso) was approved for medical use in the United States in February 2020. Meloxicam is available in combination with bupivacaine as bupivacaine/meloxicam and in combination with rizatriptan as meloxicam/rizatriptan.